KYMR
NASDAQKymera Therapeutics Inc.
Price$73.86-1.27 (-1.69%)
01:30 PM07:45 PM
News · 26 weeks97-50%
2025-12-142026-06-07
Mix5690d
- SEC Filings24(43%)
- Insider17(30%)
- Other9(16%)
- Analyst2(4%)
- Earnings2(4%)
- Leadership2(4%)
Latest news
25 items- SECSEC Form 8-K filed by Kymera Therapeutics Inc.8-K - Kymera Therapeutics, Inc. (0001815442) (Filer)
- PRKymera Therapeutics Appoints Penny Carlson as Senior Vice President, Development OperationsPenny Carlson will oversee global clinical development operations across Kymera's oral immunology portfolio Jeremy Chadwick will retire from his role as Chief Operating Officer WATERTOWN, Mass., June 08, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Penny Carlson as Senior Vice President, Development Operations. Ms. Carlson brings more than two decades of biopharmaceutical leadership experience across clinical program management, study execution and data management, with a track record of advancing n
- PRKymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS CongressesKT-579 demonstrated consistent disease-modifying activity comparable or superior to approved and clinically active therapies in multiple preclinical lupus models KT-579 Phase 1 healthy volunteer trial ongoing, with data expected in 2H26 WATERTOWN, Mass., June 08, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the presentation of new preclinical data for KT-579, its potent, selective, oral IRF5 degrader, demonstrating disease-modifying activity in lupus models. The findings show that by selectively targeting and degradin
- INSIDERChief Financial Officer Jacobs Bruce N. exercised 12,653 shares at a strike of $2.08, increasing direct ownership by 5% to 260,241 units (SEC Form 4)4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- INSIDERChief Operating Officer Chadwick Jeremy G sold $1,373,290 worth of shares (17,184 units at $79.92) as part of a pre-agreed trading plan, decreasing direct ownership by 28% to 44,018 units (SEC Form 4) to satisfy withholding obligation4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- PRKymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare ConferenceWATERTOWN, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York, NY on June 3, 2026, at 8:10 a.m. ET. A live webcast of the presentation will be available under "News and Events" in the Investors section of the Company's website at www.kymeratx.com. A replay of the webcast will be archived and available following the event. About Kymera Therapeutics Kymera is a clinical-stage biotechnology company pion
- SECSEC Form 144 filed by Kymera Therapeutics Inc.144 - Kymera Therapeutics, Inc. (0001815442) (Subject)
- SECSEC Form 144 filed by Kymera Therapeutics Inc.144 - Kymera Therapeutics, Inc. (0001815442) (Subject)
- INSIDERDirector Esposito Pamela exercised 1,000 shares at a strike of $31.20 (SEC Form 4)4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- INSIDERChief Financial Officer Jacobs Bruce N. exercised 15,000 shares at a strike of $2.08, increasing direct ownership by 6% to 247,588 units (SEC Form 4)4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Kymera Therapeutics Inc.SCHEDULE 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)
- INSIDERDirector Ridloff Elena exercised 3,000 shares at a strike of $31.20 and sold $261,000 worth of shares (3,000 units at $87.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- SECSEC Form 144 filed by Kymera Therapeutics Inc.144 - Kymera Therapeutics, Inc. (0001815442) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Kymera Therapeutics Inc.SCHEDULE 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)
- ANALYSTCanaccord Genuity initiated coverage on Kymera Therapeutics with a new price targetCanaccord Genuity initiated coverage of Kymera Therapeutics with a rating of Buy and set a new price target of $106.00
- PRKymera Therapeutics to Participate in Upcoming May Investor ConferencesWATERTOWN, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events: Bank of America 2026 Healthcare Conference in Las Vegas, NV on May 12 at 9:20 a.m. PT; andRBC Capital Markets 2026 Global Healthcare Conference in New York, NY on May 19 at 9:00 a.m. ET. Live webcasts of the presentations will be available under "News and Events" in the Investors section of the Company's website at www.kymeratx.com. Replays of the webcast
- PRKymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease WeekKT-579 demonstrated activity comparable or superior to approved and clinically active therapies in preclinical IBD models KT-579 Phase 1 healthy volunteer trial ongoing, with data expected in 2H26 WATERTOWN, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the presentation of new preclinical data for KT-579, its potent, selective, oral IRF5 degrader, demonstrating disease-modifying activity in an inflammatory bowel disease (IBD) model. The findings show that by selectively targeting and degrading IRF5, KT-57
- PRJeito Capital Bolsters Its Leadership Team With the Appointment of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, as Partner, TalentHighly experienced partners bringing 25+ years of leadership across top-tier life-sciences investment fund, pharma and Biopharma companies, driving accelerated portfolio development With leadership experience at Blackstone Life Sciences (Deputy Chief Operating Officer), Biogen, (NASDAQ:BIIB), and public and private Biopharma companies (including Kymera Therapeutics (NASDAQ: KYMR) and Cygnal Therapeutics), Elaine Caughey will support portfolio companies in strengthening operational execution, defining robust market access pathways, and enhancing their strategic value through business development support, including partnerships and acquisition transactions. She will also draw on her know
- SECSEC Form 10-Q filed by Kymera Therapeutics Inc.10-Q - Kymera Therapeutics, Inc. (0001815442) (Filer)
- SECKymera Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Kymera Therapeutics, Inc. (0001815442) (Filer)
- PRKymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business UpdateKT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively FDA granted Fast Track designation to KT-621 for the treatment of moderate to severe asthma, in addition to prior Fast Track designation for moderate to severe atopic dermatitis KT-579 (IRF5) Phase 1 healthy volunteer trial ongoing, with data expected in 2H26 Gilead Sciences exercised its option to exclusively license KT-200, a first-in-class, oral CDK2 molecular glue degrader, generating a $45 million milestone, with IND planned in 2027 Well-capitalized with $1.55 billion in cash as of March 31, 2026, and runway into 2029 Co
- INSIDERChief Executive Officer Mainolfi Nello exercised 30,000 shares at a strike of $2.08 and sold $2,435,377 worth of shares (30,000 units at $81.18) as part of a pre-agreed trading plan (SEC Form 4)4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- SECSEC Form DEFA14A filed by Kymera Therapeutics Inc.DEFA14A - Kymera Therapeutics, Inc. (0001815442) (Filer)
- SECSEC Form DEF 14A filed by Kymera Therapeutics Inc.DEF 14A - Kymera Therapeutics, Inc. (0001815442) (Filer)
- INSIDERDirector Booth Bruce exercised 5,900 shares at a strike of $14.44 and sold $539,772 worth of shares (6,000 units at $89.96) as part of a pre-agreed trading plan (SEC Form 4)4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
KYMR FAQ
7 questionsWhat does Kymera Therapeutics Inc. do?
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid...Where does KYMR stock trade?
Kymera Therapeutics Inc. (KYMR) is listed on NASDAQ.What sector and industry is KYMR in?
Kymera Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Kymera Therapeutics Inc. go public?
Kymera Therapeutics Inc. (KYMR) completed its IPO in 2020.What are analysts saying about KYMR?
Kymera Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy on 2026-05-06.What companies are similar to KYMR?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare KYMR side-by-side with any of them on Quantisnow.How can I track KYMR on Quantisnow?
Quantisnow aggregates Kymera Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KYMR to receive live email and push alerts on every new disclosure.